Discussion
Improvement of the success rate of cancer therapy
requires accurate selection of patients that will benefit
from certain therapies. However, despite the array of
biomarkers some low-risk patients will die from distant
metastasis, whereas some high-risk patients will survive
for decades. Although risk profile based on biomarkers
can help to improve the ability to discriminate between
low- and high-risk patients, accurate detection whether